

Synthesis and Antibacterial Activity of N-phenyl-3-(4-chlorophenyl)-5-(3,4-dimethoxy-phenyl) pyrazoline

Estin Nofiyanti^{1*}, Tutik Dwi Wahyuningsih³, Noer Laelly BTAG², Chairil Anwar³, Novi Nurjanah¹, Nurcholis Salman¹, Yoga Priastomo³

¹Environmental Engineering Department, Universitas Muhammadiyah Tasikmalaya, 46196 Indonesia

²Electronichal Engineering Department, Universitas Muhammadiyah Tasikmalaya, 46196 Indonesia

³Chemical Organic Laboratory, Chemistry Department, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia

*Correspondence author email: estin.nofi@umtas.ac.id

Received May 13, 2022; Accepted June 15, 2025; Available online July 20, 2025

ABSTRACT. Compound of N-phenyl-3-(4-chlorophenyl)-5-(3,4-dimethoxy-phenyl) pyrazoline was synthesized by cycloaddition reaction. The structure of the product was characterized by FTIR, ¹H-NMR and ¹³C-NMR spectrometers. The pyrazoline was screened for antibacterial activity using agar diffusion method against *Staphylococcus aureus*, *Bacillus cereus*, *Bacillus subtilis*, *Shigella flexneri*, and *Escherichia coli*. The pyrazoline had been synthesized from chalcone with phenylhydrazine to give 52.90% yield. Antibacterial screening showed that pyrazoline was active against selected gram positive bacteria. The pyrazoline was found to exhibits an antibacterial activity and its zone of inhibition/concentration against *S. aureus* (8.75/300), *B. cereus* (7.75/1000), *B. subtilis* (6.50/1000), and *E. coli* (3.50/300). The result showed that pyrazoline which was substituted with chloro and methoxy, was able to posse broad spectrum of the tested pathogenic bacteria.

Keywords: chalcone, pyrazoline, antibacterial

INTRODUCTION

Infectious diseases which caused by pathogenic bacteria are still a public health problem. WHO reported that infectious diseases are diseases with a high incidence rate and one of the biggest causes of death (World Health Organization, 2014). Antibiotics are the choice in dealing infectious diseases, especially caused by bacteria. Bacterial resistance to antibiotics was currently increasing and has become a major problem in overcoming infectious diseases in addition to the problems of toxicity and side effects (Murray et al., 2022). The development of new types of antibacterial agent needs to be done to solve this resistance problem. Indonesia is one country which has many natural products. Vanillin and its derivate is one of natural product that can used as basic material aldehyde source.

As a tropical country with numerous natural resources, Indonesia may be able to develop natural resources such as vanillin, fennel oil, clove oil, and patchouli oil as natural ingredients that can be employed as basic materials in the production of chalcone compound intermediates. One of the raw materials that can be used is a natural component. Vanillin is used to make chalcone intermediates. Vanillin is a naturally occurring substance found in the *Vanilla planifolia* plant's fruit (Arya et al., 2021).

Electron-rich nitrogen containing heterocycles such as pyrazolines have been gaining considerable amount of attention due to their important role in drug discovery. Pyrazolines possess a broad spectrum of microbial activities (Matiadis & Sagnou, 2020; Matiadis & Sagnou, 2020; Saroja et al., 2021), antidepressant activity (Popova et al., 2021; Sharma et al., 2021; Fatmayanti et al., 2024; Bhakare et al., 2025), anti-inflammatory and analgesic agents (Cuartas et al., 2020; Ouyang et al., 2021; Yasar & Zaheer, 2021; Shalaby et al., 2023; Stessel et al., 2023), anticancer activity (Matiadis & Sagnou, 2020; Tjitda et al., 2022; Fatmayanti et al., 2024), antitubercular activity (Vaddiraju et al., 2021; Gurav et al., 2022; Kumar et al., 2022; Zala et al., 2025), antioxidant activity (Lakshminarayanan et al., 2020; Mantzanidou et al., 2021; Cahyono et al., 2022; Balamon et al., 2023), anticonvulsant activity (Ray et al., 2023; Chauhan et al., 2024), antimalarial (Tiwari et al., 2021; Andhare et al., 2022), antidiabetic activity (R. S. Kumar et al., 2023; Kafali et al., 2024) and antihepatotoxic activity (Sathiya et al., 2020).

Antibiotics are the first line of defense in the fight against infectious diseases, particularly those caused by bacteria. In addition to the difficulties of toxicity and side effects, Muteeb et al. (2023) says that

bacterial resistance to antibiotics is currently increasing and is a serious difficulty in combating infectious diseases. To combat the problem of antibacterial resistance, new forms of antibacterials must be developed.

Some of pyrazoline derivatives which were substituted with *para*chloro, *para* nitro and hydroxy in pyrazoline ring C3 position had role increase antimicrobial (Farooq & Ngaini, 2022). The most popular method to synthesize pyrazolines is carried out by under acidic solvent such as using acetic acid (Saleh et al., 2020; Matiadis, 2023; Anita et al., 2024; Novaković et al., 2024). The synthesis of *N*-phenyl pyrazoline of veratraldehyde through cyclization reaction from phenylhydrazine and α,β -unsaturated ketones in acidic solvent (Mironov et al., 2021; Annes et al., 2023). The electron-donating substituents obtained from veratraldehyde were introduced to evaluate antibacterial activity by *in-vitro* assay.

The reaction of chalcone molecules with 2-phenylhydrazine can be used to make pyrazoline compounds, according to the retrosynthetic strategy. The Claisen-Schmidt condensation reaction can produce chalcone compounds as intermediates from aryl aldehyde compounds with aryl ketones. The Claisen-Schmidt condensation process follows a simple procedure that involves alkaline stirring.

EXPERIMENTAL SECTION

General remarks

All starting materials and solvents were commercially available without further purification. Melting points were measured on a Electrothermal 9100 and are uncorrected. The ^1H and ^{13}C -NMR spectra of the obtained compounds were analyzed by JEOL JNMCA 500 MHz (^1H) and 125 MHz (^{13}C) spectrometers use internal standard tetramethylsilane. IR spectra (KBr pellets) were recorded by Shimadzu prestige-21 spectrophotometer.

Synthetic procedure and characterization data

Procedure synthesis of chalcones

The aqueous sodium hydroxide (5 mL, 30%) was added into mixture of 5 mmol 4-chloroacetophenone and 5 mmol veratraldehyde in ethanol and the resulting stirred for 4 h under room temperature. The precipitation was collected and crystallized by from the appropriate solvents.

1-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)-1-propenone (**3**). Yield: 79.07%; mp: 99 °C; ν_{max} (KBr)/ cm^{-1} : 987 (C=C *trans*); 2731&2839 (C-H aldehyde), 1658 (C=O), 1157&1026 (Ar-Cl). ^1H -NMR (500 MHz, CDCl_3 , TMS) δ : 3.93 (3H, s, -OCH₃), 3.94 (3H, s, -OCH₃), 6.89 (1H, d, J = 8.40 Hz, Ar-H), 7.14 (1H, d, J = 1.95 Hz, Ar-H), 7.23 (1H, dd, J = 8.45 & 1.95 Hz, Ar-H), 7.33 (1H, d, J = 15.5 Hz, C=C *trans*), 7.46 (2H, dd, J = 8.75 & 2.00 Hz, Ar-H), 7.76 (1H, d, J = 15.5 Hz, C=C *trans*), 7.95 (2H, dd, J = 6.50 & 1.95 Hz, Ar-H). ^{13}C -NMR (125 MHz,

CDCl_3 , TMS) δ : 56.14 (OCH₃), 56.17 (OCH₃), 123.50 & 145.71 (C=C *trans*), 189.4 (C=O), 110.26, 111.29, 119.59, 127.82, 128.57, 130.01, 136.92, 139.12, 149.44, 151.78 (Ar).

General procedure for synthesis of *N*-Phenyl pyrazoline (**4**)

A solution of intermediate product (chalcone) 0.76 mmol in acetic acid glacial and phenylhydrazine (0.76 mmol) was refluxed for 4 h. The mixture was poured in crushed ice and cooled in refrigerator for 24 h. The precipitated was filtrated off, washed with aquadest and ethanol, respectively. No further purification was required.

N-phenyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl) (**4**)

Yield 52.9%; as a yellow solid; m.p. 143-144 °C. IR: ν_{max} (KBr)/ cm^{-1} : 1597 (C=N), 1242 (C-N), 1465 & 1496 (aromatic C=C), 1381 (C-O-C Methoxy). ^1H -NMR (500 MHz, CDCl_3 , TMS) δ : 3.10 (1H, dd, J = 17.00, 7.80 Hz, CH₂), 3.78 (1H, dd, J = 17.25, 12.35 Hz, CH₂), 3.81 (3H, s, OCH₃), 3.85 (3H, s, OCH₃), 5.20 (1H, dd, J = 12.32, 7.80 Hz, CH), 6.81 (1H, m, ArH), 6.87 (1H, dd, J = 8.45, 1.95 Hz, ArH), 7.08 (2H, d, J = 7.75 Hz, ArH), 7.18 (2H, t, ArH), 7.35, 7.64 (4H, d, ArH). ^{13}C -NMR (125 MHz, CDCl_3 , TMS) δ : 29.53 (CH₂), 29.87 (CH), 55.83 & 56.04 (CH₃-O), 104.60, 111.52, 121.62, 122.85, 125.70, 127.49, 129.01, 129.16, 131.56, 133.99, 140.07, 144.79, 148.72, 149.30 (Ar), 150.78 (C=N).

Antibacterial activity

The pyrazoline **4** was *in vitro* assayed by cup plate method for antibacterial activity against *Bacillus Subtilis* FNCC 0041, *Bacillus Cerreus* FNCC 0040, *Staphylococcus Aureus* FNCC 0047, *Escherichia Coli* FNCC 0091, *Shigella Flexnerii* ATCC 12022 obtained from Biotechnology laboratory, Universitas Gadjah Mada Yogyakarta, Indonesia. The tested solutions were prepared by dissolving the compound in DMSO at 100, 300, 500, 1000 $\mu\text{g/mL}$ concentrations. DMSO used as a control test to be inactive. The tested solution series were added into cup of plate and incubated at 37 °C for 24 h. The inhibition zones were measured.

RESULTS AND DISCUSSION

Chemistry

The synthesis of *N*-phenyl-3-(4-chlorophenyl)-5-(3,4-dimethoxy-phenyl) (**4**) was accomplished by cyclo-condensation of chalcones **3** (Figure1). The chalcones **3** has been synthesized from the halogenated acetophenone and veratraldehyde by Claisen-Schmidt condensation. The structures of chalcones were supported by several spectral. Thus, IR spectra showed the appearing band at 972 cm^{-1} indicated C=C *trans*. The absence bands at 2746 and 2846 cm^{-1} indicated the vibration of C-H aldehyde. ^1H -NMR spectra indicated the appearance of duplets signals (~7.20-7.70 ppm). New signals

corresponded to the allylic trans hydrogens by calculating coupling constant ($J = 15.5$ Hz); corresponding signals were also observed in ^{13}C -NMR spectra.

The compound **4** has been achieved by hetero cyclo-condensation between chalcone **3** and Phenyl hydrazine. The reactions was performed using acetic acid glacial. Cyclization of chalcone to N-Phenyl pyrazoline was proved by important spectral changes. Thus, IR spectroscopy showed the absence of the carbonyl adsorption bands ($\sim 1600\text{ cm}^{-1}$) and of the double bond allylic trans ($\sim 972\text{ cm}^{-1}$) and the presence of new adsorption band ($\sim 1597\text{ cm}^{-1}$) of heterocyclic ring. In the ^1H NMR spectra, the presence of new signals corresponded to the methylene and methine of hetero ring (~ 3.80 & ~ 5.12 ppm). ^{13}C NMR spectra confirmed the absence signals of the carbonyl and allylic trans (~ 189.5 and ~ 123.7 & ~ 145.9 ppm) and showed new signals at ~ 43.80 & ~ 56.48 ppm corresponding to the methylene and methine of hetero ring.

Biology

The compound was tested against Gram-Positive bacteria: *B. cereus* FNCC 0040, *B. Subtilis* FNCC 0041 and *S. Aureus* FNCC 0047 and against Gram-Negative bacteria: *E. Coli* FNCC 0091 and *S. Flexnerii* ATCC 12022 using agar diffusion method. The inhibitor zone values of these compounds against these bacteria are presented in **Table 1** tetracycline as known commercially antibiotic was also tested. The result showed that the compound exhibited antibacterial activities. The best of inhibition zone value was obtained against Gram-Positive bacteria *S. aureus* at $300\text{ }\mu\text{g mL}^{-1}$. Antibacterial screening showed that chloropyrazoline was active against selected gram positive bacteria. The pyrazoline was found to exhibits an antibacterial activity and its zone of inhibition/concentration against *S. aureus* (8.75/300), *B. cereus* (7.75/1000), *B. subtilis* (6.50/1000), and *E. coli* (3.50/300). The result showed that the pyrazoline which was substituted with chloro and methoxy, was found to exhibits an antibacterial activity.




Figure 1. Cyclization of the chalcone (**3**) with phenylhydrazine in acetic acid glacial form N-phenyl pyrazoline (**4**). *Reagents and conditions:* (ii) ethanol, NaOH 30%, room temperature. (iii) CH_3COOH , PhNHNH_2 , refluxed, 4 h.

Table 1. Antibacterial activity of the compound **4**

Compound	Concentration ($\mu\text{g mL}^{-1}$)	Inhibition zone (mm)				
		<i>S. aureus</i>	<i>B. cereus</i>	<i>B. subtilis</i>	<i>E. coli</i>	<i>S. flexnerii</i>
4	100	7.50	3.75	-	2.25	-
	300	8.75	2.75	-	3.50	-
	500	6.25	5.50	3.75	2.75	-
	1000	3.75	7.75	6.50	3.25	-
Tetracycline	100	20.75	20.25	20.25	12.25	14.25
DMSO	99.9%	0.75	-	-	-	-

Zone of Inhibition: -: < 1 mm (no activity); +: 1-4 (weak activity); ++: 5-9 (moderate activity); +++: 10-15 (strong activity), ++++: > 16 (Very strong activity)

CONCLUSIONS

The product of N-phenyl-3-(4-chlorophenyl)-5-(3,4-dimethoxy-phenyl) pyrazoline **4** was synthesized by cycloaddition reaction. The pyrazoline had been synthesized from derivate vanillin (veratraldehyde) to give 52.90% yield. Antibacterial screening showed that pyrazoline was active against selected gram positive bacteria. The pyrazoline was found to exhibits an antibacterial activity and its zone of inhibition/concentration against *S. aureus* (8.75/300), *B. cereus* (7.75/1000), *B. subtilis* (6.50/1000), and *E. coli* (3.50/300). The result showed that pyrazoline **4** which was substituted with chloro and methoxy, was able to posse broad spectrum of the tested pathogenic bacteria. of the tested pathogenic bacteria.

ACKNOWLEDGMENTS

The author wishes to express his gratitude to UMTAS for funding this research through internal basic research funds, as well as the Gadjah Mada University Chemistry Laboratory for allowing us to conduct sample testing.

REFERENCES

- Andhare, N. H., Anas, M., Rastogi, S. K., Manhas, A., Thopate, Y., Srivastava, K., Kumar, N., & Sinha, A. K. (2022). Synthesis and in vitro SAR evaluation of natural vanillin-based chalcones tethered quinolines as antiplasmodial agents. *Medicinal Chemistry Research*, 31(12), 2182–2194. <https://doi.org/10.1007/s00044-022-02975-y>
- Anita, A., Chouhan, L. K., Ameta, S., Sharma, V., & Ranawat, P. S. (2024). Synthesis of pyrazoline derivatives and their pharmacological activities: A Review of the last decade. *Chemistryselect*, 9(9). <https://doi.org/10.1002/slct.202304483>
- Annes, S. B., Perumal, K., Anandhakumar, K., Shankar, B., & Ramesh, S. (2023). Transition-metal-free dehydrogenation of benzyl alcohol for C–C and C–N bond formation for the synthesis of pyrazolo[3,4-b]pyridine and pyrazoline derivatives. *Journal of Organic Chemistry*, 88(9), 6039–6057. <https://doi.org/10.1021/acs.joc.3c00382>
- Arya, S. S., Rookes, J. E., Cahill, D. M., & Lenka, S. K. (2021). Vanillin: A Review on the therapeutic prospects of a popular flavouring molecule. *Advances in Traditional Medicine*, 21(3), 415–431. <https://doi.org/10.1007/s13596-020-00531-w>
- Balamon, M. G., El-Bordany, E. A., Mahmoud, N. F. H., Hamed, A. A., & Swilem, A. E. (2023). Exploring the antioxidant potency of new naphthalene-based chalcone derivatives: Design, synthesis, antioxidant evaluation, docking study, DFT calculations. *Chemistry & Biodiversity*, 20(12). <https://doi.org/10.1002/cbdv.202301344>
- Bhakare, M. P., Rayeesahmad, Md. Rayeesahmad, M., A.A, S., Gujrathi, D., Siral, V., & Sonaldoltade. (2025). Synthesis and evalution of pyrazole derivatives by different method. *International Journal of Pharmaceutical Research and Applications*, 10(2), 734–743. <https://doi.org/10.35629/4494-1002734743>
- Cahyono, R. N., Andari, S. A., & Wahyuningsih, T. D. (2022). Synthesis of N-phenylpyrazoline derivative from 4-chlorobenzaldehyde and 4-Chloroacetophenone and Its Activity as an antimalarial agent. *Materials Science Forum*, 1061, 211–216. <https://doi.org/10.4028/p-wah85x>
- Chauhan, A., Salahuddin, S., Mazumder, A., Kumar, R., Ahsan, M. J., Yar, M. S., Maqsood, R., & Singh, S. K. (2024). Targeted development of pyrazoline derivatives for neurological disorders: A Review. *Chemistryselect*, 9(16). <https://doi.org/10.1002/slct.202400738>
- Cuartas, V., Robledo, S. M., Vélez, I. D., Crespo, M. d. P., Sortino, M., Zacchino, S., Nogueras, M., Cobo, J., Upegui, Y., Pineda, T., Yepes, L., & Insuasty, B. (2020). New thiazolyl-pyrazoline derivatives bearing nitrogen mustard as potential antimicrobial and antiprotozoal agents. *Archiv Der Pharmazie*, 353(5). <https://doi.org/10.1002/ardp.201900351>
- Farooq, S., & Ngaini, Z. (2022). Microwave-assisted synthesis, antimicrobial activities and molecular docking of methoxycarboxylated chalcone derived pyrazoline and pyrazole derivatives. *Chemistryselect*, 7(1). <https://doi.org/10.1002/slct.202103984>
- Fatmayanti, B. R., Habibie, A., & Dhey, A. K. (2024). Synthesis of chalcone and pyrazoline derivatives with acetophenone and veratraldehyde as precursors. *Medical Sains : Jurnal Ilmiah Kefarmasian*, 9(3), 655–664. <https://doi.org/10.37874/ms.v9i3.1274>
- Gurav, R., Nalawade, R. D., Sawant, S. D., Satyanarayan, N. D., Sankpal, S., & Hangirgekar, S. (2022). Biosynthesis of ZrO₂ for ZrO₂@Ag-S-CH₂COOH as the retrievable catalyst for the one-pot green synthesis of pyrazoline derivatives and their anticancer evaluation. *Applied Organometallic Chemistry*, 36(5). <https://doi.org/10.1002/aoc.6666>
- Kafali, M. E., Finos, M. A., & Τσούπρας, Α. (2024). Vanillin and Its derivatives: A critical review of their anti-inflammatory, anti-infective, wound-healing, neuroprotective, and anti-cancer health-promoting benefits. *Nutraceuticals*, 4(4), 522–561. <https://doi.org/10.3390/nutraceuticals4040030>
- Kumar, R. S., Naveena, S., Sekar, P., & Yogadharshini, N. (2023). Therapeutic aspects of biologically potent vanillin derivatives: A critical review.

- Journal of Drug Delivery and Therapeutics*, **13**(7), 177–189. <https://doi.org/10.22270/jddt.v13i7.6159>
- Kumar, S., Saini, A., Kumar, A., Raj, R., & Kumar, V. (2022). 7-Chloroquinoline-chalcone-pyrazoline conjugates: synthesis, antimycobacterial and cytotoxic activities. *Journal of Heterocyclic Chemistry*, **59**(9), 1513–1518. <https://doi.org/10.1002/jhet.4486>
- Lakshminarayanan, B., Kannappan, N., Subburaju, T., & Kalaichelvan, V. K. (2020). Synthesis of some novel 3-(4-ethoxyphenyl)-5-(4-substituted)-4,5-dihydro-1h-pyrazole derivatives as potent antioxidant agents. *International Journal of Research in Pharmaceutical Sciences*, **11**(2), 1571–1577. <https://doi.org/10.26452/ijrps.v11i2.2035>
- Mantzanidou, M., Pontiki, E., & Hadjipavlou-Litina, D. (2021). Pyrazoles and pyrazolines as anti-inflammatory agents. *Molecules*, **26**(11), 3439. <https://doi.org/10.3390/molecules26113439>
- Matiadis, D. (2023). Strategies and methods for the synthesis of 2-pyrazolines: recent developments (2012–2022). *Advanced Synthesis & Catalysis*, **365**(12), 1934–1969. <https://doi.org/10.1002/adsc.202300373>
- Matiadis, D., & Sagnou, M. (2020). pyrazoline hybrids as promising anticancer agents: an up-to-date overview. *International Journal of Molecular Sciences*, **21**(15), 1–41. <https://doi.org/10.3390/ijms21155507>
- Mironov, M. E., Борисов, С. А., Rybalova, T. V., Baev, D. S., Толстикова, Т. Г., & Shults, E. E. (2021). Synthesis of anti-inflammatory spirostene-pyrazole conjugates by a consecutive multicomponent reaction of diosgenin with oxalyl chloride, arylalkynes and hydrazines or hydrazones. *Molecules*, **27**(1), 162. <https://doi.org/10.3390/molecules27010162>
- Murray, C. J., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines-Woodhouse, G., Kashef Hamadani, B. H., Kumaran, E. A. P., McManigal, B., ... Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *Lancet*, **399**(10325), 629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023). Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A Narrative review. *Pharmaceuticals*, **16**(11), 1615. <https://doi.org/10.3390/ph16111615>
- Novaković, S. B., Bogdanović, G. A., Ratković, Z., Blagojević, S., Matić, S., & Muškinja, J. (2024). Synthesis, structural properties and DNA protective activity of ferrocenyl N-acyl pyrazolines. *Applied Organometallic Chemistry*, **38**(6). <https://doi.org/10.1002/aoc.7464>
- Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., & Wu, Q. (2021). Chalcone derivatives: Role in anticancer therapy. *Biomolecules*, **11**(6), 894. <https://doi.org/10.3390/biom11060894>
- Popova, S. A., Pavlova, E. V., Shevchenko, O. G., Chukicheva, I. Y., & Kutchin, A. V. (2021). Isobornylchalcones as scaffold for the synthesis of diarylpyrazolines with antioxidant activity. *Molecules*, **26**(12), 2–17. <https://doi.org/10.3390/molecules26123579>
- Ray, P. K., Salahuddin, S., Mazumder, A., Kumar, R., Ahsan, M. J., & Yar, M. S. (2023). Synthesis, anticonvulsant, and molecular docking studies of (3,5-disubstituted-4,5-dihydro-1h-pyrazol-1-yl) (4-chlorophenyl) methanone derivatives. *Indian Journal of Pharmaceutical Education and Research*, **57**(1), 202–209. <https://doi.org/10.5530/001954641727>
- Saleh, M., Ayoub, A. I., & Hammady, A. O. (2020). Synthesis biological studies of some new heterocyclic compound derived from 2-chloro-3-formyl quinoline and 4-(benzyl sulfonyl) acetophenone. *Egyptian Journal of Chemistry*, **63**(12), 4769–4776. <https://doi.org/10.21608/ejchem.2020.26354.2535>
- Saroja, T., Ezhilarasi, R. M., Selvamani, V., & Mahalakshmi, S. (2021). Synthesis, characterization and in-silico analysis of new 2-pyrazolines. *Journal of Scientific Research*, **13**(1), 183–194. <https://doi.org/10.3329/jsr.v13i1.46995>
- Sathiya, S., Keerthika, A., Krishnamoorthy, B. S., Nandhabala, S., Aravind, S., Hari, N., & Ravikumar, R. V. S. S. N. (2020). Synthesis of novel pyrazolines and their antimicrobial activity. *RASAYAN Journal of Chemistry*, **13**(01), 676–683. <https://doi.org/10.31788/rjc.2020.1315568>
- Shalaby, M. A., Fahim, A. M., & Rizk, S. A. (2023). Antioxidant activity of novel nitrogen scaffold with docking investigation and correlation of DFT stimulation. *RSC Advances*, **13**(21), 14580–14593. <https://doi.org/10.1039/d3ra02393a>
- Sharma, P., Singh, M., & Mathew, B. (2021). An update of synthetic approaches and structure-activity relationships of various classes of human MAO-B inhibitors. *Chemistryselect*, **6**(7), 1404–1429. <https://doi.org/10.1002/slct.202004188>
- Stessel, B., Lambrechts, M., Evers, S., Vanderstappen, C., Callebaut, I., Ory, J.-P., Herbots, J., Dreesen, I., Vaninbrouckx, M., & Velde, M. V. d. (2023). Additive or synergistic analgesic effect of metamizole on standard pain treatment at

- home after arthroscopic shoulder surgery. *European Journal of Anaesthesiology*, 40(3), 171–178. <https://doi.org/10.1097/eja.0000000000001792>
- Tiwari, A., Bendi, A., & Bhathiwal, A. S. (2021). An overview on synthesis and biological activity of chalcone derived pyrazolines. *Chemistryselect*, 6(45), 12757–12795. <https://doi.org/10.1002/slct.202103779>
- Tjitda, P. J. P., Jumina, J., & Wahyuningsih, T. D. (2022). Synthesis, molecular docking, and ADMET study of N1-hydrogen and N1-benzoyl pyrazoline as antibacterial agents. *Chiang Mai University Journal of Natural Sciences*, 21(3). <https://doi.org/10.12982/cmujns.2022.048>
- Vaddiraju, N., Ajitha, M. J., & Rajnarayana, K. (2021). Synthesis, characterization and evaluation of antidiabetic activity of novel pyrazoline fused indole derivatives. *Journal of Pharmaceutical Research International*, 276–292. <https://doi.org/10.9734/jpri/2021/v33i52b33627>
- World Health Organization. (2014). Antimicrobial resistance global report on surveillance. In Section 01: *Resistance to antibacterial drugs* (pp. 1–5). WHO Press. <https://doi.org/10.1016/j.giec.2020.06.004>
- Yasar, Q., & Zaheer, Z. (2021). 4-Aminoantipyrine analogs as anti-inflammatory and antioxidant agents: synthesis, biological evaluation and molecular docking studies. *International Journal of Pharmaceutical Investigation*, 11(1), 14–22. <https://doi.org/10.5530/ijpi.2021.1.4>
- Zala, M. J., Vora, J. J., Khedkar, V. M., Almalki, A. H., Tivari, S. R., & Jatvada, R. (2025). Development of novel sulfonamide-based pyrazole-clubbed pyrazoline derivatives: synthesis, biological evaluation, and molecular docking study. *ACS Omega*, 10(7), 7120–7130. <https://doi.org/10.1021/acsomega.4c10198>